<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Iranian Biomedical Journal</title>
<title_fa>مجله بیومدیکال ایران</title_fa>
<short_title>IBJ</short_title>
<subject>Basic Sciences</subject>
<web_url>http://ibj.pasteur.ac.ir</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>1028-852X</journal_id_issn>
<journal_id_issn_online>2008-823X</journal_id_issn_online>
<journal_id_pii>-</journal_id_pii>
<journal_id_doi>10.61882/ibj</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>-</journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science>-</journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1400</year>
	<month>6</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2021</year>
	<month>9</month>
	<day>1</day>
</pubdate>
<volume>25</volume>
<number>5</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Leishmania Parasite: the Impact of New Serum-Free Medium as an Alternative for Fetal Bovine Serum</title>
	<subject_fa>Molecular Immunology &amp; Vaccines</subject_fa>
	<subject>Molecular Immunology &amp; Vaccines</subject>
	<content_type_fa>مقاله کامل</content_type_fa>
	<content_type>Full Length/Original Article</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;strong&gt;Background: &lt;/strong&gt;Flagellated protozoan of the genus &lt;em&gt;Leishmania&lt;/em&gt; is the causative agent of vector-borne parasitic diseases of leishmaniasis. Since the production of recombinant pharmaceutical proteins requires the cultivation of host cells in a serum-free medium, the elimination of FBS can improve the possibility of large-scale culture of &lt;em&gt;Leishmania &lt;/em&gt;parasite. In the current study, we aimed at evaluating a new serum-free medium in &lt;em&gt;Leishmania &lt;/em&gt;parasite culture for future live &lt;em&gt;Leishmania&lt;/em&gt; vaccine purposes. &lt;strong&gt;Methods: &lt;/strong&gt;Recombinant &lt;em&gt;L. tarentolae&lt;/em&gt; secreting PpSP15-EGFP and wild type &lt;em&gt;L. major&lt;/em&gt; were cultured in serum-free (complete serum-free medium [CSFM]) and serum-supplemented medium. The growth rate, protein expression, and infectivity of cultured parasites in both conditions was then evaluated and compared. &lt;strong&gt;Results: &lt;/strong&gt;Diff-Quick staining and epi-fluores&amp;shy;cence microscopy examination displayed the typical morphology of&lt;em&gt; L. major &lt;/em&gt;and&lt;em&gt; L. tarentolae-&lt;/em&gt;PpSP15-EGFP promastigote grown in CSFM medium. The amount of EGFP expression was similar in CSMF medium compared to M199 supplemented with 5% FBS in flow cytometry analysis of &lt;em&gt;L. tarentolae&lt;/em&gt;-PpSP15-EGFP parasite. Also, a similar profile of PpSP15-EGFP proteins was recognized in Western blot analysis of &lt;em&gt;L. tarentolae-&lt;/em&gt;PpSP15-EGFP cultured in CSMF and the serum-supplemented medium. Footpad swelling and parasite load measurements showed the ability of CSFM medium to support the &lt;em&gt;L. major&lt;/em&gt; infectivity in BALB/C mice.&lt;strong&gt; Conclusion: &lt;/strong&gt;This study demonstrated that CSFM can be a promising substitute for FBS supplemented medium in parasite culture for live vaccination purposes.&lt;br&gt;
&lt;gdiv&gt;&lt;/gdiv&gt;&lt;gdiv&gt;&lt;/gdiv&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Growth rate, L. major, L. tarentolae, Serum-free medium, PpSP15-EGFP protein</keyword>
	<start_page>349</start_page>
	<end_page>358</end_page>
	<web_url>http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-4430-1&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Sima</first_name>
	<middle_name></middle_name>
	<last_name>Habibzadeh</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>Simahabibzade@gmail.com</email>
	<code></code>
	<orcid>0000-0001-8036-8419</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Immunology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Delaram</first_name>
	<middle_name></middle_name>
	<last_name>Doroud</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>d_doroud@yahoo.com</email>
	<code></code>
	<orcid>0000-0003-4167-9921</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Quality Control Department, Production and Research Complex, Pasteur institute of Iran, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Tahereh</first_name>
	<middle_name></middle_name>
	<last_name>Taheri</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>tahereh_t@yahoo.com</email>
	<code></code>
	<orcid>0000-0002-2619-6879</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Negar</first_name>
	<middle_name></middle_name>
	<last_name>Seyed</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>negarse@gmail.com</email>
	<code></code>
	<orcid>0000-0001-8249-6692</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Sima</first_name>
	<middle_name></middle_name>
	<last_name>Rafati</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>s_rafati@yahoo.com</email>
	<code></code>
	<orcid>0000-0002-7221-1320</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Department of Immunotherapy and Leishmania Vaccine Research, Pasteur Institute of Iran, Tehran, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
